Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 25c, misses on revenue

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($1.45), $0.25 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $22.42 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Palo Alto Networks stock dips despite quarterly beat, raised profit outlook
• Amtech Systems closes $60 million public stock offering